Total Payments
$2,782
2024 Payments
$665.51
Companies
28
Transactions
134
Medicare Patients
21,311
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$2,736 (98.3%)
Education$46.16 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,736 | 128 | 98.3% |
| Education | $46.16 | 6 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $355.45 | 21 | $0 (2024) |
| Amgen Inc. | $330.64 | 20 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $317.94 | 15 | $0 (2024) |
| PFIZER INC. | $210.17 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $167.90 | 7 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $166.23 | 11 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $164.56 | 9 | $0 (2024) |
| HEARTFLOW, INC. | $160.48 | 2 | $0 (2024) |
| Artivion, Inc. | $117.15 | 1 | $0 (2024) |
| Daiichi Sankyo Inc. | $105.82 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $665.51 | 21 | HEARTFLOW, INC. ($160.48) |
| 2023 | $299.42 | 15 | Novartis Pharmaceuticals Corporation ($91.73) |
| 2022 | $152.28 | 9 | Novartis Pharmaceuticals Corporation ($62.36) |
| 2020 | $15.58 | 1 | Novartis Pharmaceuticals Corporation ($15.58) |
| 2019 | $28.98 | 2 | Tactile Systems Technology Inc ($14.82) |
| 2018 | $631.07 | 32 | Amgen Inc. ($140.41) |
| 2017 | $988.91 | 54 | Amgen Inc. ($190.23) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Cardiovascular | ||||||
| 10/04/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Not Applicable | ||||||
| 09/17/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $146.78 | General |
| Category: Coronary | ||||||
| 08/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: DIABETES | ||||||
| 07/16/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.55 | General |
| 06/27/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/19/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Genetic Disease | ||||||
| 06/11/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Not Applicable | ||||||
| 06/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Heart Failure | ||||||
| 05/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/05/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $13.70 | General |
| Category: Coronary | ||||||
| 04/02/2024 | Artivion, Inc. | Cardiac non-SynerGraft (Device), CRYOVALVE SG PULMONARY HUMAN HEART VALVE, BIOGLUE SURGICAL ADHESIVE | Food and Beverage | In-kind items and services | $117.15 | General |
| Category: Cardiovascular surgery | ||||||
| 03/27/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/28/2024 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/07/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/16/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/03/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.70 | General |
| Category: Not Applicable | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 6,247 | 8,848 | $4.2M | $501,342 |
| 2022 | 21 | 5,465 | 7,803 | $3.4M | $404,223 |
| 2021 | 20 | 5,032 | 7,358 | $3.1M | $371,249 |
| 2020 | 23 | 4,567 | 6,425 | $2.7M | $330,869 |
Total Patients
21,311
Total Services
30,434
Medicare Billing
$1.6M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 796 | 1,189 | $653,950 | $132,126 | 20.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 599 | 602 | $1.2M | $99,576 | 8.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 558 | 711 | $266,625 | $47,056 | 17.6% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 215 | 234 | $62,002 | $30,064 | 48.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 168 | 676 | $520,520 | $28,576 | 5.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,141 | 2,044 | $296,380 | $25,208 | 8.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 368 | 378 | $264,600 | $21,217 | 8.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 135 | 135 | $134,595 | $19,310 | 14.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 42 | 88 | $124,520 | $17,704 | 14.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 95 | 179 | $92,901 | $13,114 | 14.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 181 | 183 | $85,461 | $10,890 | 12.7% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 214 | 218 | $57,986 | $10,200 | 17.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,038 | 1,403 | $61,732 | $9,701 | 15.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 56 | $79,296 | $8,721 | 11.0% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 105 | 105 | $124,950 | $6,449 | 5.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 58 | $41,470 | $6,442 | 15.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 51 | 51 | $28,560 | $3,469 | 12.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 213 | 283 | $5,808 | $2,370 | 40.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 34 | 47 | $9,635 | $2,227 | 23.1% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 23 | 23 | $20,895 | $2,097 | 10.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 22 | 22 | $3,872 | $1,582 | 40.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 23 | 23 | $2,484 | $807.07 | 32.5% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 15 | 16 | $4,112 | $561.84 | 13.7% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Office | 2023 | 22 | 22 | $14,815 | $517.93 | 3.5% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 21 | 21 | $9,240 | $500.85 | 5.4% |
About Robert Zaloom
Robert Zaloom is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1437151016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Zaloom has received a total of $2,782 in payments from pharmaceutical and medical device companies, with $665.51 received in 2024. These payments were reported across 134 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($2,736).
As a Medicare-enrolled provider, Zaloom has provided services to 21,311 Medicare beneficiaries, totaling 30,434 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 08/12/2005
- Last Updated 06/28/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1437151016
Products in Payments
- Corlanor (Drug) $313.40
- ELIQUIS (Drug) $256.13
- PRADAXA (Drug) $225.88
- ENTRESTO (Drug) $218.64
- VERQUVO (Drug) $167.90
- XARELTO (Drug) $166.23
- FFRct (Device) $160.48
- LEQVIO (Drug) $136.81
- Cardiac non-SynerGraft (Device) $117.15
- VYNDAQEL (Drug) $96.28
- JARDIANCE (Drug) $92.06
- Savaysa (Drug) $83.74
- LifeVest (Device) $77.56
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS (Device) $65.05
- Arcalyst (Drug) $56.15
- FUROSCIX (Drug) $45.27
- CardioMEMS HF System (Device) $44.64
- BYSTOLIC (Drug) $34.68
- Epi-Sense Guided Coagulation System with VisiTrax, Models (Device) $30.69
- MULTAQ (Drug) $30.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799